Underweight maintained with empirically calibrated 10-15% trim into $268-272; structural stop at $263, avoiding biotech rotation in favor of cash/Treasuries
Underweight rating maintained with empirically calibrated 10-15% trim (not the 25-40% proposed by the aggressive trader) based on the dispositive 8/27 evidence that confirmed breakdown + light volume reliably produces squeeze risk on AAA-rated defensive compounders that momentum frameworks systematically underweight. The 21.78x forward P/E embedding 43% EPS growth ($8.61 TTM → $12.31 forward) against 4-5% organic growth is unsustainable, particularly with Q2 EBITDA margins contracting (37.09% → 35.64%) and a largely unbuffered $9B biosimilar cliff in 2026-2028, but the institutional floor effect (64-year dividend streak, AAA-equivalent credit, $19.3B FCF, 0.23 beta, $7B talc reserve already absorbed) prevents sizing the trim at the magnitude the technical setup alone might suggest. The modest trim captures the asymmetric near-term technical risk (3-4% upside vs. 2-4% downside to $263 and 5-7% downside to $255) while preserving structural-moat exposure that activates institutional dip-buyers on weakness.
| Position | Action |
|---|---|
| Price at $268-272 with light-volume rejection | Execute modest 10-15% trim (recalibrated from trader's proposed 25-40% based on 8/27 empirical evidence on AAA-rated defensive compounders) |
| Reject mid-cap biotech rotation thesis | Redeploy trim proceeds to cash or short-duration Treasuries yielding 4%+ in 89% no-cut regime |
| Seeking sector exposure | Consider healthcare names that haven't already rallied 54% YTD for better risk/reward |
JNJ at $268 is one of the best risk-adjusted opportunities in large-cap healthcare, combining defensive characteristics (0.23 beta) with accelerating revenue growth, first-in-class approvals, and a post-Kenvue earnings normalization that could drive further multiple expansion.
| Indicator | Value | Signal |
|---|---|---|
| close | 268.04 | neutral |
| 200_sma | 231.46 | bullish |
| 50_sma | 256.98 | bullish |
| 10_ema | 267.45 | neutral |
| rsi | 57.07 | bullish |
| macd | 4.06 | bullish |
| macd_signal | 4.05 | neutral |
| macd_histogram | 0.02 | neutral |
| bollinger_middle | 263.10 | neutral |
| bollinger_upper | 276.08 | neutral |
| bollinger_lower | 250.11 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $250-256 with RSI >45 and no MACD bearish crossover
Then: Upgrade to Hold
The 0.23 beta provides extraordinary defensive characteristics that justify premium valuation
↩ rebuts: “Bear concerns about valuation being 'stretched'”
EV: +10–20% on re-rating to higher-quality pharma multiple · concedes: Stelara LOE is a real $9B+ headwind — bears correctly identify the risk, even if the bull argues it's being absorbed; Net debt did triple from $7.5B to $28.2B — though the bull attributes this to growth-oriented M&A rather than dividend funding; Tangible book value is negative — true for JNJ and all branded pharma peers, but still a valid data point; The 54% YTD surge does mean some near-term upside has been captured
JNJ at $268 is a richly priced, legally encumbered, debt-loaded compounder facing aggressive biosimilar cliffs, where the stock has rallied 54% YTD on institutional crowding rather than fundamental improvement, creating asymmetric downside risk with no margin of safety.
EV: -$8.3% (to $250-255 over 1-3 months) · concedes: The forward P/E of 21.78x is mathematically accurate given 2025 EPS of $11.03; Revenue has continued to grow despite Stelara loss-of-exclusivity (LOE); JNJ has strong dividend growth history and AAA-quality credit history (though recently downgraded to AA+); The balance sheet has $71.5B in stockholders' equity (2024) growing to $81.5B (2025); Tremfya, Carvykti, Caplyta, and Imaavy represent real replacement assets for Stelara, though not dollar-for-dollar absorption
→ vs neutral: Uptrend intact with price above all moving averages is actually a melt-up running out of fuel, not a comfort; 15.8% extension from 200 SMA on 0.23 beta name is the problem, not the support; MACD histogram at 0.02 is a dashboard warning light, not momentum confirmation
→ vs conservative: AAA balance sheet, 60 years of dividend increases, 25.7% ROE, and moat narrative don't protect against multiple compression when macro regime shifts; historical data shows identical setups (forward P/E above 21x, PEG above 4) resulted in underperformance versus index over 24 months for Pfizer in 2021, Merck in 2022, and AbbVie in 2023; talc litigation tail remains an unresolved risk
| atr | 5.44 | neutral |
| vwma_60d | 266.24 | bullish |
Support: 263.1 · 256.98 · 250.11 | Resistance: 267.45 · 273.14 · 276.08
Johnson & Johnson is in a confirmed intermediate- and long-term uptrend, trading 15.8% above its 200 SMA with healthy medium-term alignment. Short-term momentum is pausing rather than reversing—the flat MACD histogram at 0.02 and price hovering at the 10 EMA suggest consolidation. RSI remains in a constructive bullish zone at 57.07 with no overbought conditions. The risk/reward favors trend-following strategies, with a constructive Hold bias recommended while monitoring for either a breakout above $273.14 or a pullback to the $263 support zone.
Market Cap
$645.95 B
52-Week High
$276.47
52-Week Low
$173.33
50-Day Avg Price
$257.47
200-Day Avg Price
$233.49
P/E (TTM)
31.13x
Forward P/E
21.78x
PEG Ratio
4.78
Price / Book
7.60x
Dividend Yield
2.02%
Beta
0.231
Revenue (2025)
$94,193 M
Revenue YoY Growth (2025)
+6.0%
Gross Profit (2025)
$63,937 M
Gross Margin
67.9%
Operating Income (2025)
$25,596 M
Operating Margin
27.2%
R&D Expense (2025)
$14,665 M
SG&A (2025)
$23,676 M
EBITDA (2025)
$41,055 M
Net Income (2025)
$26,804 M
Net Margin
28.5%
Diluted EPS (2025)
$11.03
Cash & Equivalents (2025)
$19,709 M
Total Current Assets (2025)
$55,624 M
Goodwill (2025)
$48,772 M
Intangibles (2025)
$50,403 M
Total Assets (2025)
$199,210 M
Total Debt (2025)
$47,933 M
Long-Term Debt (2025)
$39,438 M
Stockholders' Equity (2025)
$81,544 M
Net Debt (2025)
$28,224 M
Current Ratio (2025)
1.09
Debt-to-Equity (2025)
57.7%
Operating Cash Flow (2025)
$24,530 M
CapEx (2025)
($5,217) M
Free Cash Flow (2025)
$19,313 M
Acquisitions (2025)
($17,541) M
Dividends Paid (2025)
($12,381) M
Buybacks (2025)
($5,953) M
Return on Equity (ROE)
25.7%
Return on Assets (ROA)
8.6%
Profit Margin
21.5%
FCF Margin
~20.5%
5Y Revenue CAGR
~4.5%
5Y FCF CAGR
~3%
Price Position vs 200-Day MA
+13%
Strengths
Concerns
JNJ is a fundamentally top-tier, defensive compounder with industry-leading cash returns ($19.3B FCF), AAA-quality operations, and a deep pharma pipeline. Revenue grew from $79.9B (2022) to $94.2B (2025), with net income rebounding sharply to $26.8B in 2025 from the litigation-driven trough of $14.1B in 2024. The forward P/E of 21.78x is reasonable, but the PEG ratio of 4.78x and the stock trading 13% above its 200-day MA indicate valuation is full, offering balanced rather than asymmetric reward/risk. The company is aggressively deploying capital via M&A ($17.5B in acquisitions in 2025, including the $14.6B Intra-Cellular/Caplyta deal), which is expanding goodwill and intangibles but also increasing integration risk. Dividend aristocrat status and a beta of 0.23 make it a defensive portfolio stabilizer, but income investors should note the 2.02% yield is below the 5-year average of ~2.5–2.7%.
Macro: Fed policy: 89% probability of no rate cuts in 2026 (Polymarket, $7.6M volume). Low US recession probability at 8%. Inflation tail risk rising: 12% probability >4.5%, 8% probability >5%, 6% probability >6%. Kevin Warsh (potential Fed chair candidate) flagging inflation persistence per WSJ (2026-08-27). FRED macro data unavailable due to missing API key. Higher-for-longer backdrop historically favors dividend-paying healthcare mega-caps like JNJ.